Brachytherapy pp 123-134 | Cite as

Asian Cooperation and Global Trends in Brachytherapy for Cervical Cancer

  • Shingo KatoEmail author


Brachytherapy plays an important role in the treatment of cervical cancer. Japan is a pioneer of high-dose-rate brachytherapy for cervical cancer and has made great contributions in the establishment of optimal therapy for this disease over the course of five decades. Japanese institutions have recently conducted several clinical studies of three-dimensional image-guided brachytherapy. Based on these experiences, several Japanese institutions have conducted international cooperative activities on radiotherapy for cervical cancer with other Asian countries for over 20 years.


Cervical cancer High-dose-rate brachytherapy Three-dimensional image-guided brachytherapy International cooperation FNCA IAEA/RCA 


  1. 1.
    Henschke UK, Hilaris BS, Mahan GD. Remote afterloading with intracavitary applicators. Radiology. 1964;83:344–5.CrossRefPubMedGoogle Scholar
  2. 2.
    O’Connell D, Howard N, Joslin CAF, Ramsey NW, Liversage WE. A new remotely controlled unit for the treatment of uterine carcinoma. Lancet. 1965;18:570–1.CrossRefGoogle Scholar
  3. 3.
    Arai T, Morita S, Iinuma T, et al. Radiation treatment of cervix cancer using high dose rate remote after-loading intracavitary irradiation: an analysis of the correlation between optimal dose range and fractionation. Jpn J Cancer Clin. 1979;25:605–12.Google Scholar
  4. 4.
    Arai T, Morita S, Kutsutani Y, et al. Relationship between total iso-effect dose and number of fractionations for the treatment of uterine cervical carcinoma by high dose rate intracavitary irradiation. In: Bates TD, Berry RJ, editors. High dose rate afterloading in the treatment of cancer of the uterus. London: Br J Rad Special Report 17; 1980. p. 89–92.Google Scholar
  5. 5.
    Japan Society of Obstetrics and Gynecology, The Japanese Pathological Society, and Japan Radiological Society, editors. The general rules for clinical and pathological management of uterine cervical cancer. Tokyo: Kanehara Shuppan; 1987.Google Scholar
  6. 6.
    Arai T, Nakano T, Morita S, Sakashita K, Nakamura YK, Fukuhisa K. High-dose-rate remote afterloading intracavitary radiation therapy for cancer of the uterine cervix: a 20-year experience. Cancer. 1992;69:175–80.CrossRefPubMedGoogle Scholar
  7. 7.
    Nakano T, Kato S, Ohno T, et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer. 2005;103:92–101.CrossRefPubMedGoogle Scholar
  8. 8.
    Teshima T, Inoue T, Ikeda H, et al. High-dose rate and low dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka university hospital. Cancer. 1993;72:2409–14.CrossRefPubMedGoogle Scholar
  9. 9.
    Hareyama M, Sakata K, Oouchi A, et al. High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer. 2002;94:117–24.CrossRefPubMedGoogle Scholar
  10. 10.
    FNCA - Forum for Nuclear Cooperation in Asia. Available at: Accessed on 1 Oct 2017.
  11. 11.
    International Agency for Research on Cancer. GLOBOCAN 2012. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available at: Accessed on 1 Oct 2017.
  12. 12.
    Nakano T, Kato S, Cao J, et al. A regional cooperative clinical study of radiotherapy for cervical cancer in east and southeast Asian countries. Radiother Oncol. 2007;84:314–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Ohno T, Nakano T, Kato S, et al. Accelerated hyperfractionated radiotherapy for cervical cancer: multi-institutional prospective study of forum for nuclear cooperation in Asia among eight Asian countries. Int J Radiat Oncol Biol Phys. 2008;70:1522–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative Para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol. 1999;17:1339–48.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and Para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a gynecologic oncology group study. J Clin Oncol. 2007;25:2804–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and Para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22:872–80.CrossRefPubMedGoogle Scholar
  19. 19.
    Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Lukka H, Hirte H, Fyles A, et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer-a meta-analysis. Clin Oncol. 2002;14:203–12.CrossRefGoogle Scholar
  21. 21.
    Vale C, Tierney JF. Stewart LA, et al. for chemotherapy for cervical Cancer meta-analysis collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systemic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802–12.CrossRefGoogle Scholar
  22. 22.
    Kato S, Ohno T, Thephamongkhol K, et al. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in east and south-East Asia. Int J Radiat Oncol Biol Phys. 2010;77:751–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Kato S, Ohno T, Thephamongkhol K, et al. Long-term follow-up results of a multi-institutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and Southeast Asia. Int J Radiat Oncol Biol Phys. 2013;87:100–5.CrossRefPubMedGoogle Scholar
  24. 24.
    The south east Asian radiation oncology group - SEAROG Available at: Accessed on 1 Oct 2017.
  25. 25.
    Federation of Asian Organizations for Radiation Oncology – FARO Available at: Accessed on 1 Oct 2017.
  26. 26.
    Mizuno H, Fukuda S, Fukumura A, et al. Multicentre dose audit for clinical trials of radiation therapy in Asia. J Radiat Res. 2017;58:372–7.PubMedGoogle Scholar
  27. 27.
    International Atomic Energy Agency The Regional Cooperative Agreement for research, development and training related to nuclear science and technology for Asia and Pacific - IAEA/RCA Available at: Accessed on 1 Oct 2017.
  28. 28.
    The Transition from 2-D Brachytherapy to 3-D High Dose Rate Brachytherapy Available at: Accessed on 1 Oct 2017.
  29. 29.
    Haie-Meder C, Pötter R, Limbergen EV, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74:235–45.CrossRefPubMedGoogle Scholar
  30. 30.
    Pötter R, Haie-Meder C, Limbergen EV, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy - 3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67–77.CrossRefPubMedGoogle Scholar
  31. 31.
    Kirisits C, Pötter R, Lang S, et al. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2005;62:901–11.CrossRefPubMedGoogle Scholar
  32. 32.
    Georg P, Pötter R, Georg D, et al. Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys. 2012;82:653–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Pötter R, Dimopoulos J, Bachtiary B, et al. 3D conformal HDR-brachy- and external beam therapy plus simultaneous cisplatin for high-risk cervical cancer: clinical experience with 3 year follow-up. Radiother Oncol. 2006;79:80–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Dimopoulos J, Lang S, Kirisits C, et al. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys. 2009;75:56–63.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Georg P, Kirisits C, Goldner G, et al. Correlation of dose-volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy. Radiother Oncol. 2009;91:173–80.CrossRefPubMedGoogle Scholar
  36. 36.
    Kato S, Tran DNL, Ohno T, et al. CT-based 3D dose-volume parameters of the rectum and late rectal complications in patients with cervical cancer treated with high-dose-rate intracavitary brachytherapy. J Radiat Res. 2010;51:215–21.CrossRefPubMedGoogle Scholar
  37. 37.
    Isohashi F, Yoshida Y, Koizumi M, et al. Rectal dose and source strength of the high-dose-rate Iridium-192 both affect late rectal bleeding after intracavitary radiation therapy for uterine cervical carcinoma. Int J Radiat Oncol Biol Phys. 2010;77:758–64.CrossRefPubMedGoogle Scholar
  38. 38.
    Yoshida K, Yamazaki H, Takenaka T, et al. A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer. Int J Radiat Oncol Biol Phys. 2010;77:765–72.CrossRefPubMedGoogle Scholar
  39. 39.
    Pötter R, Georg P, Dimopoulos J, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol. 2011;100:116–23.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Wakatsuki M, Ohno T, Yoshida D, et al. Intracavitary combined with CT-guided interstitial brachytherapy for locally advanced uterine cervical cancer: introduction of the technique and a case presentation. J Radiat Res. 2011;52:54–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Oike T, Ohno T, Noda S, et al. Can combined intracavitary/interstitial approach be an alternative to interstitial brachytherapy with the Martinez universal perineal interstitial template (MUPIT) in computed tomography-guided adaptive brachytherapy for bulky and/or irregularly shaped gynecological tumors? Radiat Oncol. 2014;9:222–8.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Murakami N, Kasamatsu T, Wakita A, et al. CT based three dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer. BMC Cancer. 2014;14:447–53.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Sturdza A, Pötter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016;120:428–33.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Fokdal L, Sturdza A, Mazeron R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: analysis from the retroEMBRACE study. Radiother Oncol. 2016;120:434–40.CrossRefPubMedGoogle Scholar
  45. 45.
    International Commission on Radiation Units and Measurements (ICRU) Report 89. Prescribing, recording, and reporting brachytherapy for cancer of the cervix. J ICRU. 2013;13Google Scholar
  46. 46.
    Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy: a survey of the American brachytherapy society. Int J Radiat Oncol Biol Phys. 2010;76:104–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Grover S, Harkenrider MM, Cho LP, Erickson B, Small C, Small W Jr, et al. Image guided cervical brachytherapy: 2014 Survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2016;94:598–604.Google Scholar
  48. 48.
    Pavamani S, D’Souza DP, Portelance L, Craighead PS, Pearce AG, Traptow LL, et al. Image-guided brachytherapy for cervical cancer: a Canadian Brachytherapy Group survey. Brachytherapy. 2011;10:345–51.Google Scholar
  49. 49.
    Tan LT. Implementation of image-guided brachytherapy for cervix cancer in the UK: progress update. Clin Oncol. 2011;23:681–4.CrossRefGoogle Scholar
  50. 50.
    van Dyk S, Byram D, Bernshaw D. Use of 3D imaging and awareness of GEC-ESTRO recommendations for cervix cancer brachytherapy throughout Australia and New Zealand. J Med Imaging Radiat Oncol. 2010;54:383–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Ohno T, Toita T, Tsujino K, et al. A questionnaire-based survey on 3D image-guided brachytherapy for cervical cancer in Japan: advances and obstacles. J Radiat Res. 2015;56:897–903.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Toita T, Ohno T, Ikushima H, et al. JASTRO Brachytherapy Group 19th meeting abstract. 2017; 54.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Radiation OncologySaitama Medical University International Medical CenterHidakaJapan

Personalised recommendations